Xylem Inc.
107.64USD
-1.1700 (-1.08%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.45▼ | $1.46 | 5 | 11 |
| Next quarter | $1.65▲ | $1.63 | 12 | 4 |
| Current year | $5.66▲ | $5.53 | 21 | 0 |
| Next year | $6.25▲ | $6.09 | 17 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.34 | $1.46 | +0.12 (+9.2%) |
| 2026-03-31 | $1.08 | $1.12 | +0.04 (+3.3%) |
| 2025-12-31 | $1.41 | $1.42 | +0.01 (+0.8%) |
| 2025-09-30 | $1.23 | $1.37 | +0.14 (+11.1%) |
259 ratings from 42 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Jefferies | Maintained | Buy | $145 $150 | Aug 24, 2026 |
| UBS | Maintained | Neutral | $135 $138 | Aug 13, 2026 |
| UBS | Maintained | Neutral | $129 $135 | Jul 30, 2026 |
| Stifel | Maintained | Buy | $157 $160 | Jul 29, 2026 |
| Mizuho | Maintained | Neutral | $124 $130 | Jul 29, 2026 |
| RBC Capital | Maintained | Outperform | $159 $164 | Jul 29, 2026 |
| Barclays | Maintained | Overweight | $154 $159 | Jul 29, 2026 |
| Baird | Maintained | Outperform | $163 $165 | Jul 29, 2026 |
| Stifel | Maintained | Buy | $159 $157 | Jul 20, 2026 |
| RBC Capital | Maintained | Outperform | $157 $159 | Jul 16, 2026 |
| Jefferies | Upgraded from Hold | Buy | $130 $140 | Jun 25, 2026 |
| UBS | Maintained | Neutral | $132 $133 | Apr 29, 2026 |
| Citigroup | Maintained | Buy | $174 $168 | Apr 29, 2026 |
| Oppenheimer | Maintained | Outperform | $160 $158 | Apr 29, 2026 |
| Barclays | Maintained | Overweight | $156 $154 | Apr 29, 2026 |
| Stifel | Maintained | Buy | $163 $159 | Apr 29, 2026 |
| UBS | Downgraded from Buy | Neutral | $152 $132 | Apr 21, 2026 |
| JP Morgan | Maintained | Overweight | $170 $160 | Apr 16, 2026 |
| Stifel | Maintained | Buy | $175 $163 | Apr 14, 2026 |
| UBS | Maintained | Buy | $155 $152 | Apr 9, 2026 |
| Oppenheimer | Reiterated | Outperform | $165 $160 | Apr 1, 2026 |
| RBC Capital | Maintained | Outperform | $176 $162 | Feb 11, 2026 |
| Stifel | Maintained | Buy | $178 $175 | Feb 11, 2026 |
| Citigroup | Maintained | Buy | $182 $174 | Feb 11, 2026 |
| Barclays | Maintained | Overweight | $166 $156 | Feb 11, 2026 |
68 filings from 22 insiders · 13 buy / 1 sell over 6m
Officers and directors of XYL, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| van der Berg Andrea MicheleOfficer, EVP & Chief Financial Officer | GrantStock Options (Right to Buy) | 6.0k | $106.89 | $645k | Sep 1, 2026 |
| van der Berg Andrea MicheleOfficer, EVP & Chief Financial Officer | Grant | 1.7k | — | — | Sep 1, 2026 |
| Johnston Joseph PatrickOfficer, EVP & President, AW | GrantStock Options (Right to Buy) | 2.3k | $106.89 | $246k | Sep 1, 2026 |
| Johnston Joseph PatrickOfficer, EVP & President, AW | Grant | 645 | — | — | Sep 1, 2026 |
| KOCH DALE CHRISTIANDirector | Grant | 1.2k | $120.27 | $150k | Aug 13, 2026 |
| FRIEL ROBERT FDirector | Grant | 2.5k | $116.88 | $290k | May 14, 2026 |
| GLATCH LISADirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| MORELLI MARK DDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| PERIBERE JEROME ADirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| TRETIKOV LILADirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| YADAV UDAYDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| HARKER VICTORIA DDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| ELLIS EARL RAYDirector | Grant | 1.7k | $116.88 | $200k | May 14, 2026 |
| MCSHANE GERI-MICHELLEOfficer | Sell | 4.3k | $117.46 | $501k | May 7, 2026 |
| MCSHANE GERI-MICHELLEOfficer | Exercise | 3.1k | $86.76 | $273k | May 7, 2026 |
| PERIBERE JEROME ADirector | Buyindirect | 1.2k | $116.61 | $141k | May 4, 2026 |
| TOUSSAINT CLAUDIA SOfficer | Grant | 9.4k | — | $954k | Mar 2, 2026 |
| AULICK RODNEY OOfficer | Grant | 1.6k | — | — | Mar 2, 2026 |
| MCSHANE GERI-MICHELLEOfficer | Grant | 2.8k | — | $285k | Mar 2, 2026 |
| PINE MATTHEW FRANCISChief Executive Officer | Grant | 30.8k | — | $1.89M | Mar 2, 2026 |
No analyst notes on XYL yet.
Analyst Ratings
16 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 10 | 7 | 0 | 0 | Buy2.14 |
| 1 mo ago | 3 | 11 | 9 | 0 | 0 | Buy2.26 |
| 2 mo ago | 4 | 11 | 8 | 0 | 0 | Buy2.17 |